Validation of the Brazilian Version of Functional Assessment of Cancer Therapy-Prostate—FACT-P (Version 4) in Prostate Cancer Patients

被引：0
作者：
Priscila Antonichelli de Held
Wagner Eduardo Matheus
Angela Maria Elizabeth Piccolotto Naccarato
Roberta Cunha Matheus Rodrigues
Aline Akel Ferruccio
Ubirajara Ferreira
机构：
[1] State University of Campinas (Unicamp),Department of Urology, School of Medical Sciences
[2] State University of Campinas,Faculty of Nursing
[3] Brazil (Unicamp),undefined
来源：
Journal of Cancer Education | 2022年 / 37卷
关键词：
Prostate cancer; FACT-P (version 4); Quality of life; Questionnaires; Validation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The purpose of this study is to validate the Brazilian version of Functional Assessment of Cancer Therapy-Prostate FACT-P (version 4) in nonmetastatic prostate cancer (PC) patients. Patients with histopathological diagnosis of PC were submitted to health-related quality of life (HRQOL) questionnaires – SF-36 (Medical Outcomes Study 36 – Item Short-Form Health Survey) and FACT-P (version 4). After 7 to 15 days, FACT-P (version 4) was reapplied in the sample’s percentage that participated the first evaluation. Cronbach alpha coefficient was used to determine internal consistency and intraclass correlation coefficient (ICC) certified stability. Correlations between FACT-P (version 4) and SF-36 tested convergent validity. Regarding known groups validity, the hypothesis tested was that FACT-P (version 4) is capable of discriminating HRQOL in patients with different PC risk classifications. A total of 112 patients with nonmetastatic PC were evaluated. Cronbach alpha coefficients (0.64–0.88) and ICC (0.75–0.93) obtained satisfactory results of reliability. Verified correlations (r 0.3–0.72) between FACT-P (version 4) and SF-36 suggest convergent validity. In the studied sample, FACT-P (version 4) was unable to discriminate HRQOL in nonmetastatic patients. The Brazilian version of FACT-P questionnaire (version 4) showed evidences of reliability and validity on evaluating HRQOL in Brazilian men with nonmetastatic PC.
引用
收藏
页码：1760 / 1767
页数：7
相关论文
共 135 条
  • [1] Mottet N(2017)EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent Eur Urol 71 618-629
  • [2] Bellmunt J(2008)Management of complications of prostate cancer treatment CA A Cancer J Clin 58 196-213
  • [3] Bolla M(2017)When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers Cancer Treat Rev 58 14-21
  • [4] Michaelson MD(2015)Long-term follow-up of a large active surveillance cohort of patients with prostate cancer J Clin Oncol 33 272-277
  • [5] Cotter SE(2016)Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer N Engl J Med 375 1425-1437
  • [6] Gargollo PC(2017)Quality of life outcomes after primary treatment for clinically localised prostate cancer: a systematic review Eur Urol 72 869-885
  • [7] Zietman AL(2015)Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study J Cancer Surviv 9 361-372
  • [8] Dahl DM(2014)Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments Qual Life Res 23 2169-2181
  • [9] Smit MR(2015)Measuring health-related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity Urol Oncol 33 69.e19-28
  • [10] Stavrinides V(2018)Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial Lancet Oncol 19 194-206
12345678910